• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.62% Nasdaq Up0.35%

    ImmunoCellular Therapeutics, Ltd. (IMUC)

    0.22 Up 0.00(0.56%) 4:00PM EST
    ProfileGet Profile for:
    ImmunoCellular Therapeutics, Ltd.
    23622 Calabasas Road
    Suite 300
    Calabasas, CA 91302
    United States - Map
    Phone: 818-264-2300
    Fax: 818-224-5287
    Website: http://www.imuc.com

    Index Membership:N/A
    Full Time Employees:5

    Business Summary 

    ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers; and ICT-140 for ovarian cancer. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. ImmunoCellular Therapeutics, Ltd. has a research collaboration agreement with the University of Maryland focusing on immunotherapies for cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on ImmunoCellular Therapeutics, Ltd.

    Corporate Governance 
    ImmunoCellular Therapeutics, Ltd.’s ISS Governance QuickScore as of Jul 1, 2013 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Gary S. Titus CPA, 56
    Chairman of The Board, Corp. Sec., Chairman of Audit Committee, Member of Fin. Committee and Member of Compensation Committee
    Mr. Andrew Gengos , 52
    Chief Exec. Officer, Pres and Director
    Mr. David E. Fractor CPA, 56
    Chief Financial Officer, Principal Accounting Officer, VP of Fin. and Treasurer
    Dr. Anthony J. Gringeri Ph.D., 62
    Sr. VP of Strategic Resources
    Dr. John S. Yu M.D., Ph.D., 52
    Founder, Consultant and Director
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders